HYFTNasdaqPharmaceutical PreparationsFiscal year ends April 30
MindWalk Holdings Corp.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 20-F on Jul 23, 2026
$1.32+0.01 (+0.76%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2019 to 2026
Gross margin
58.8%−5.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +46.4% | -9.0% | -2.8% | – | |
| Gross profit | +59.6% | -7.5% | -4.5% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Current ratio | – | 8.05 | 2.80 | |
| Inventory turnover | – | 6.3× | 5.0× | |
| Capex to revenue | – | 7.7% | 2.6% | |
| Diluted shares | – | 16M | 46M |
Where the cash went
Fiscal 2022 to 2026, five years combined
MindWalk generated C$51.81M from operations and spent C$5.16M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
C$51.81M
Used
C$5.16M
Capital expenditureC$5.16M100%DividendsC$00%Share buybacksC$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
3of 5 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-C$12.46M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-C$12.46M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.08 → 2.80
- No dilutionShare count did not rise33M → 46M
- Gross margin improvedGross margin up on the prior year53.93% → 58.80%
- More efficientAsset turnover rose0.18 → 0.35